Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16151 ↗At a glance
Randomisierte kontrollierte Studie in British Journal of Clinical Pharmacology, 2024. Written by Sheng Yang and 5 co-authors. Institution: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Major MEDLINE topics: Breast Neoplasms, Polyethylene Glycols, Granulocyte Colony-Stimulating Factor, Neutropenia. Cited 2 times so far (Crossref); 34 references. Funded by: CAMS Innovation Fund for Medical Sciences (CIFMS), National Natural Science Foundation Fund of China, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.
Topics: Onkologische Pflege
Abstract (original language)
Aims
The recommended dosage of pegylated recombinant human granulocyte‐colony stimulating factor (PEG‐rhG‐CSF) for Western chemotherapy patients is 6 mg per cycle. However, for Eastern Asians, the optimal dose remains unknown.
Methods
This open‐label, randomized, non‐inferiority trial (NCT05283616) enrolled Chinese female breast cancer patients receiving adjuvant chemotherapy. Participants were randomized to receive either 3 or 6 mg of PEG‐rhG‐CSF per cycle, stratified by body weight (BW; ≤60 kg vs . >60 kg). The primary endpoint was timely absolute neutrophil count (ANC) recovery before the second cycle of chemotherapy.
Results
A total of 122 patients were randomized and 116 were included for efficacy analyses. The timely ANC recovery rate in the 3 mg arm was 89.8%, compared to 93.0% in the 6 mg arm (one‐sided 95% confidence interval [CI] lower limit for difference: −11.7%), meeting the prespecified non‐inferiority margin of 15%. The rate was 93.3% with PEG‐rhG‐CSF 3 mg and 96.6% with 6 mg in patients with BW ≤ 60 kg, and 86.2% and 89.3%, respectively, in those with BW > 60 kg. Although the incidence of severe neutropenia was similar across arms, the occurrence of excessively high ANC and white blood cell counts was higher in the 6 mg arm. No grade ≥3 adverse events related to PEG‐rhG‐CSF occurred.
Conclusion
Three milligrams of PEG‐rhG‐CSF per cycle provided non‐inferior neutrophil protection and attenuated neutrophil overshoot compared to 6 mg doses. This low‐dose regimen could be a new supportive care option for Chinese breast cancer patients receiving anthracycline‐based adjuvant chemotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
ORCID profiles: Pin Zhang
Funding
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Natural Science Foundation Fund of China
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Cite
APA
Yang, S., Chen, S. S., Zhang, C. G., Zhou, Y. L., Xiu, M., & Zhang, P. (2024). Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16151
Vancouver
Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P. Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16151
BibTeX
@article{Yang2024,
author = {Yang, Sheng and Chen, Shan-Shan and Zhang, Chang-Gong and Zhou, Ying-Lei and Xiu, Meng and Zhang, Pin},
title = {Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16151}
}
EUVIMED